$289.29
Live
0.4%
Downside
Day's Volatility :1.47%
Upside
1.07%
8.4%
Downside
52 Weeks Volatility :35.94%
Upside
30.07%
Period | West Pharmaceutical Services Inc | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | -7.77% | 3.6% | 6.5% |
6 Months | -21.85% | 10.2% | 18.1% |
1 Year | -20.84% | 19.6% | 38.8% |
3 Years | -30.53% | 16.8% | 28.9% |
Market Capitalization | 20.9B |
Book Value | $35.49 |
Dividend Share | 0.79 |
Dividend Yield | 0.28% |
Earnings Per Share (EPS) | 7.02 |
PE Ratio | 41.12 |
PEG Ratio | 5.01 |
Wall Street Target Price | 343.46 |
Profit Margin | 18.25% |
Operating Margin TTM | 18.45% |
Return On Assets TTM | 10.66% |
Return On Equity TTM | 19.72% |
Revenue TTM | 2.9B |
Revenue Per Share TTM | 39.01 |
Quarterly Revenue Growth YOY | -6.9% |
Gross Profit TTM | 1.1B |
EBITDA | 756.8M |
Diluted Eps TTM | 7.02 |
Quarterly Earnings Growth YOY | -0.27 |
EPS Estimate Current Year | 6.51 |
EPS Estimate Next Year | 7.8 |
EPS Estimate Current Quarter | 1.74 |
EPS Estimate Next Quarter | 2.12 |
What analysts predicted
Upside of 18.73%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 1.7B | ↑ 7.4% |
Net Income | 206.9M | ↑ 37.29% |
Net Profit Margin | 12.05% | ↑ 2.63% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 1.8B | ↑ 7.13% |
Net Income | 241.7M | ↑ 16.82% |
Net Profit Margin | 13.14% | ↑ 1.09% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 2.1B | ↑ 16.69% |
Net Income | 346.2M | ↑ 43.24% |
Net Profit Margin | 16.13% | ↑ 2.99% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 2.8B | ↑ 31.89% |
Net Income | 661.8M | ↑ 91.16% |
Net Profit Margin | 23.37% | ↑ 7.24% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 2.9B | ↑ 1.95% |
Net Income | 585.9M | ↓ 11.47% |
Net Profit Margin | 20.3% | ↓ 3.07% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 2.9B | ↑ 2.18% |
Net Income | 593.4M | ↑ 1.28% |
Net Profit Margin | 20.12% | ↓ 0.18% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 716.6M | ↑ 1.11% |
Net Income | 140.0M | ↑ 35.92% |
Net Profit Margin | 19.54% | ↑ 5.01% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 753.8M | ↑ 5.19% |
Net Income | 155.1M | ↑ 10.79% |
Net Profit Margin | 20.58% | ↑ 1.04% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 747.4M | ↓ 0.85% |
Net Income | 161.3M | ↑ 4.0% |
Net Profit Margin | 21.58% | ↑ 1.0% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 732.0M | ↓ 2.06% |
Net Income | 137.0M | ↓ 15.07% |
Net Profit Margin | 18.72% | ↓ 2.86% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 695.4M | ↓ 5.0% |
Net Income | 115.3M | ↓ 15.84% |
Net Profit Margin | 16.58% | ↓ 2.14% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 702.0M | ↑ 0.95% |
Net Income | 111.3M | ↓ 3.47% |
Net Profit Margin | 15.85% | ↓ 0.73% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.6B | ↓ 14.52% |
Total Liabilities | 196.1M | ↓ 0.46% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 2.3B | ↑ 47.04% |
Total Liabilities | 768.2M | ↑ 291.74% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 2.8B | ↑ 19.32% |
Total Liabilities | 939.3M | ↑ 22.27% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 3.3B | ↑ 18.61% |
Total Liabilities | 978.4M | ↑ 4.16% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 3.6B | ↑ 9.14% |
Total Liabilities | 931.9M | ↓ 4.75% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 3.8B | ↑ 5.88% |
Total Liabilities | 948.5M | ↑ 1.78% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.7B | ↑ 2.95% |
Total Liabilities | 947.4M | ↑ 1.66% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.7B | ↓ 1.45% |
Total Liabilities | 922.9M | ↓ 2.59% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.8B | ↑ 2.32% |
Total Liabilities | 886.5M | ↓ 3.94% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.8B | ↑ 1.99% |
Total Liabilities | 948.5M | ↑ 6.99% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 3.6B | ↓ 5.93% |
Total Liabilities | 921.7M | ↓ 2.83% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 3.5B | ↓ 3.13% |
Total Liabilities | 912.6M | ↓ 0.99% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 288.6M | ↑ 9.61% |
Investing Cash Flow | -100.8M | ↓ 24.55% |
Financing Cash Flow | -80.7M | ↓ 25.96% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 367.2M | ↑ 27.23% |
Investing Cash Flow | -228.0M | ↑ 126.19% |
Financing Cash Flow | -36.8M | ↓ 54.4% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 472.5M | ↑ 28.68% |
Investing Cash Flow | -179.5M | ↓ 21.27% |
Financing Cash Flow | -137.1M | ↑ 272.55% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 584.0M | ↑ 23.6% |
Investing Cash Flow | -253.1M | ↑ 41.0% |
Financing Cash Flow | -168.1M | ↑ 22.61% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 724.0M | ↑ 23.97% |
Investing Cash Flow | -288.2M | ↑ 13.87% |
Financing Cash Flow | -293.6M | ↑ 74.66% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 138.1M | ↓ 40.16% |
Investing Cash Flow | -82.1M | ↓ 13.4% |
Financing Cash Flow | -71.0M | ↑ 647.37% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 169.2M | ↑ 22.52% |
Investing Cash Flow | -82.1M | ↑ 0.0% |
Financing Cash Flow | -176.8M | ↑ 149.01% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 230.1M | ↑ 35.99% |
Investing Cash Flow | -259.9M | ↑ 216.57% |
Financing Cash Flow | -22.3M | ↓ 87.39% |
Sell
Neutral
Buy
West Pharmaceutical Services Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
West Pharmaceutical Services Inc | -4.37% | -21.85% | -20.84% | -30.53% | 109.39% |
Intuitive Surgical, Inc. | 6.56% | 41.26% | 91.18% | 53.45% | 177.85% |
Resmed Inc. | -2.51% | 33.07% | 63.68% | -8.76% | 83.88% |
Becton, Dickinson And Company | 3.84% | 4.22% | -4.76% | -1.1% | -4.07% |
Alcon Ag | -2.89% | 18.03% | 30.76% | 16.68% | 62.63% |
Cooper Companies Inc., The | -1.41% | 20.24% | -66.42% | 5.22% | 50.71% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
West Pharmaceutical Services Inc | 41.12 | 41.12 | 5.01 | 6.51 | 0.2 | 0.11 | 0.0 | 35.49 |
Intuitive Surgical, Inc. | 81.54 | 81.54 | 4.08 | 6.65 | 0.16 | 0.08 | NA | 41.4 |
Resmed Inc. | 34.67 | 34.67 | 2.0 | 7.71 | 0.23 | 0.13 | 0.01 | 33.11 |
Becton, Dickinson And Company | 48.07 | 48.07 | 1.11 | 13.11 | 0.06 | 0.03 | 0.02 | 89.5 |
Alcon Ag | 42.58 | 42.58 | 3.58 | 3.06 | 0.05 | 0.03 | 0.0 | 42.35 |
Cooper Companies Inc., The | 59.32 | 59.32 | 11.0 | 3.66 | 0.05 | 0.03 | NA | 39.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
West Pharmaceutical Services Inc | Buy | $20.9B | 109.39% | 41.12 | 18.25% |
Intuitive Surgical, Inc. | Buy | $168.3B | 177.85% | 81.54 | 27.65% |
Resmed Inc. | Buy | $35.2B | 83.88% | 34.67 | 21.79% |
Becton, Dickinson And Company | Buy | $69.5B | -4.07% | 48.07 | 7.13% |
Alcon Ag | Buy | $46.6B | 62.63% | 42.58 | 11.44% |
Cooper Companies Inc., The | Buy | $21.3B | 50.71% | 59.32 | 9.45% |
Insights on West Pharmaceutical Services Inc
Revenue is up for the last 2 quarters, 695.4M → 702.0M (in $), with an average increase of 0.9% per quarter
Netprofit is down for the last 4 quarters, 161.3M → 111.3M (in $), with an average decrease of 11.5% per quarter
In the last 1 year, Intuitive Surgical, Inc. has given 95.3% return, outperforming this stock by 114.6%
In the last 3 years, Intuitive Surgical, Inc. has given 53.4% return, outperforming this stock by 83.9%
Vanguard Group Inc
BlackRock Inc
Bank of New York Mellon Corp
State Street Corp
Artisan Partners Limited Partnership
Franklin Resources Inc
In the quarter ending March,2024. West Pharmaceutical Services Inc has declared dividend of $0.20
Read Morewest works side-by-side with healthcare partners from concept to the patient, designing and manufacturing packaging and delivery systems that promote efficiency, reliability and safety. west leads the way with cutting-edge technologies and quality systems, a thorough understanding of global regulatory compliance, and an unmatched knowledge of relevant pharmaceutical product testing, development and packaging. west supports customers from sales, manufacturing, and research and development locations in north and south america, europe, asia and australia.
Organization | West Pharmaceutical Services Inc |
Employees | 10600 |
CEO | Mr. Eric M. Green |
Industry | Health Technology |
Pnc Financial Services Group, Inc.
$289.29
-1.37%
Mid-cap Value Etf Vanguard
$289.29
-1.37%
Unilever Plc
$289.29
-1.37%
Sirius Xm Holdings Inc.
$289.29
-1.37%
Airbnb
$289.29
-1.37%
Caterpillar Inc.
$289.29
-1.37%
Ishares Core Dividend Growth Etf
$289.29
-1.37%
Tenet Healthcare Corp.
$289.29
-1.37%
W.r. Berkley Corporation
$289.29
-1.37%